InhalerMRP Under Process
Official PMBI MRP is being updated for catalog code 2575.
Locate Jan Aushadhi KendraClinical Overview
Ipratropium Bromide Inhaler (20mcg) and Respirator Solution (250mcg per ml) is an inhaled synthetic quaternary ammonium anticholinergic bronchodilator on the WHO Model List of Essential Medicines. It competitively antagonizes muscarinic M1, M2, and M3 receptors on bronchial smooth muscle, blocking acetylcholine released from parasympathetic vagal efferents. Because of its quaternary structure, it does not cross mucosal membranes or the blood-brain barrier, exerting localized bronchodilation with minimal systemic anticholinergic adverse effects. Indicated for maintenance bronchodilation and acute relief of bronchospasm in Chronic Obstructive Pulmonary Disease (COPD) and adjunctive management of severe acute asthma.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Inhaler: Inhale 2 puffs four times daily at regular intervals (maximum 12 puffs daily). Respirator solution: Administer 250 to 500 mcg diluted in 0.9% NaCl via a jet nebulizer over 10-15 minutes. Protect eyes during administration.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Dry mouth (xerostomia), bitter taste, throat irritation, cough, headache, dizziness, nausea. Rare/Severe: Acute angle-closure glaucoma (if sprayed in eyes), urinary retention (in BPH), and paradoxical bronchospasm.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Do NOT allow mist or spray to enter the eyes (can precipitate acute angle-closure glaucoma and pupillary dilation). Use with caution in patients with narrow-angle glaucoma or bladder outlet obstruction.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, pulmonological diagnosis, or respiratory management recommendations. Inhalation therapies and allergy medications should be used strictly under the guidance of a qualified pulmonologist or registered medical practitioner.
Levosalbutamol 1.25mg + Ipratropium 500mcg Respules
Salbutamol (100mcg) and Ipratropium Bromide (20mcg Inhaler) combines a short-acting beta-2 agonist (SABA) with a short-acting muscarinic antagonist (SAMA) on the WHO Model List of Essential Medicines. Salbutamol relaxes bronchial smooth muscle via cyclic AMP elevation; ipratropium blocks vagal acetylcholine-mediated bronchoconstriction at muscarinic M3 receptors. This dual-pathway approach produces greater, longer-lasting bronchodilation than either agent alone without added sympathomimetic side effects. Indicated for management of bronchospasm in Chronic Obstructive Pulmonary Disease (COPD) and acute severe asthma exacerbations.
Salbutamol 100mcg + Ipratropium 20mcg Inhaler
Salbutamol (100mcg) and Ipratropium Bromide (20mcg Inhaler) combines a short-acting beta-2 agonist (SABA) with a short-acting muscarinic antagonist (SAMA) on the WHO Model List of Essential Medicines. Salbutamol relaxes bronchial smooth muscle via cyclic AMP elevation; ipratropium blocks vagal acetylcholine-mediated bronchoconstriction at muscarinic M3 receptors. This dual-pathway approach produces greater, longer-lasting bronchodilation than either agent alone without added sympathomimetic side effects. Indicated for management of bronchospasm in Chronic Obstructive Pulmonary Disease (COPD) and acute severe asthma exacerbations.
Levosalbutamol 100mcg + Ipratropium 40mcg Rotacap
Salbutamol (100mcg) and Ipratropium Bromide (20mcg Inhaler) combines a short-acting beta-2 agonist (SABA) with a short-acting muscarinic antagonist (SAMA) on the WHO Model List of Essential Medicines. Salbutamol relaxes bronchial smooth muscle via cyclic AMP elevation; ipratropium blocks vagal acetylcholine-mediated bronchoconstriction at muscarinic M3 receptors. This dual-pathway approach produces greater, longer-lasting bronchodilation than either agent alone without added sympathomimetic side effects. Indicated for management of bronchospasm in Chronic Obstructive Pulmonary Disease (COPD) and acute severe asthma exacerbations.